Drug intelligence / Profile preview

SKY-1800

Development stage: Unknown
Lead developer: Skyhawk Therapeutics
Modality: Small Molecules

Overview

**SKY-1800** is an investigational small molecule developed by Skyhawk Therapeutics using their proprietary SKYSTAR™ RNA-splicing platform. It functions as a **RNA splicing modulator**, a class of therapies designed to alter pre-mRNA splicing to reduce expression of disease-causing proteins. While specific indications and targets are not publicly detailed, it represents an early-stage candidate akin to Skyhawk's lead asset SKY-0515 for Huntington's disease, potentially targeting RNA-mediated pathologies in rare neurological disorders.[4]

Beyond the preview

Go deeper on SKY-1800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKY-1800.

Explore the full profile